May 21, 2020 / 1:21 AM / 10 days ago

BRIEF-Akeso Says Antibody Novel Drug Obtained Approval From NMPA For Registrational Trial

May 21 (Reuters) - Akeso Inc:

* PD-1/CTLA-4 BI-SPECIFIC ANTIBODY NOVEL DRUG OBTAINED APPROVAL FROM NMPA TO INITIATE REGISTRATIONAL TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below